The consortium, in collaboration with the University of Liverpool and academic institutes in Guangdong, China, focussed on the development of new drug therapies for the treatment of tuberculosis, malaria, neglected tropical diseases and other infectious diseases.
The collaboration has been extended to include the South China University of Technology (SCUT), International Healthcare Innovation Institute (Jiangmen) and Wuyi University. The group has developed several UK/China co-funded initiatives in the critical area of AMR.